Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer.

Trial Profile

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Paclitaxel (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Interim results (retrospective analysis, n = 21) assessing NLR as a prognostic indicator presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results of interim analysis (n=21) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 03 Jan 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top